Company Overview - Weike Technology specializes in the research, design, manufacturing, and sales of precision injection molds and has expanded into the production and sales of injection parts and health products [1] - The company has developed into a large-scale "mold integration" production enterprise, serving global Fortune 500 clients [1] - Since its establishment, Weike has focused on precision injection molds while actively extending its industrial chain to downstream products [1] Technological Innovation - Weike holds over 500 patents, including 27 authorized invention patents, and has received multiple honors such as "Key Backbone Enterprise in Precision Injection Molding" and "National High-tech Enterprise" [2] Revenue Growth - In the first three quarters of 2024, the main growth areas were in new energy, small home appliances, and outdoor home products [3] - The new energy sector, which began resource investment in early 2022, saw rapid sales growth in 2023, focusing on components for power batteries and electric vehicles [3] - The small home appliance sector entered a peak season in the second half of 2023, influenced by market trends and external factors [3] - The outdoor home segment experienced growth due to the expansion of North American brand clients [3] Financial Performance - The company's operating cash flow has been 1.1 times its net profit over the past three years, indicating strong profitability [4] - Factors contributing to high profitability include technological leadership, customized small-batch production, and a client base of large, reputable companies [4] Profit Margin Stability - The company's gross margin is relatively stable but may experience a gradual decline due to product structure adjustments and increased domestic market share [5] - Future strategies will focus on acquiring high-tech clients to maintain gross margin levels [5] Material Applications - Weike utilizes PEEK materials in products such as electronic cigarettes and medical sterilization devices, showcasing advanced production techniques [6] Robotics and Smart Products - The company produces components for robotics, including motor parts and gears for educational and automated feeding robots [7] - Collaborations with leading companies in cooling technology have led to the development of smart driving cockpit components [8] Acquisition Strategy - The acquisition of Yuke aimed to enhance customer resources and technical capabilities, transitioning from a secondary to a primary supplier for major clients [9] - Yuke specializes in injection parts for automotive and medical sectors, focusing on high-value technologies [9] Future Goals - Weike aims for a 20% increase in net profit for 2025, with a focus on the automotive sector and high-tech clients [10] - The company has over 1.4 billion yuan in cash assets, which will be used for strategic acquisitions in the automotive and small appliance sectors [11]

Company Overview - Weike Technology specializes in the research, design, manufacturing, and sales of precision injection molds and has expanded into the production and sales of injection parts and health products, serving various industries including automotive and electronics [1][2]. - The company has developed into a large-scale "mold-integration" production enterprise and has established overseas production bases in Germany, Malaysia, Mexico, the USA, Singapore, and Vietnam since 2019 to enhance its global operational layout [2]. Financial Performance - In the first three quarters of 2024, the revenue breakdown by sector is as follows: Fashion Appliances 33%, Automotive 29%, Home 18%, with significant growth in the New Energy, Small Appliances, and Outdoor Home sectors [3][4]. - The company aims for a net profit growth target of 20% for 2025, which aligns with its employee equity incentive plan [16]. Product and Market Strategy - The New Energy sector has seen rapid growth since early 2022, with sales of components for electric vehicle batteries and capacitors increasing significantly in 2023 [5][7]. - The Fashion Appliances sector's growth is attributed to a complete manufacturing platform that reduces costs and accelerates product delivery, with plans to expand into new product categories [9]. Competitive Advantages - Weike Technology holds over 500 patents, including 27 authorized invention patents, and has been recognized as a key enterprise in precision injection molds and a national-level technology center [2]. - The company benefits from a strong customer base, primarily consisting of Fortune 500 companies, which provides a stable revenue stream and favorable payment terms [10][11]. Challenges and Risk Management - The company faces longer payment cycles from domestic New Energy clients but maintains sufficient funds to manage cash flow effectively [8]. - To mitigate risks associated with accounts receivable, the company conducts credit assessments and closely monitors payment progress [8]. International Sales and Production - In the first three quarters of 2024, the company's export ratio is approximately 42%, with actual figures expected to exceed 60% due to certain sales classified as domestic [13]. - The overseas sales distribution is as follows: North America 29%, Europe 30%, and Asia 39% [13]. Future Outlook - The company plans to increase overseas investments to enhance its international competitiveness while maintaining a primary focus on domestic production capacity [17]. - Weike Technology is committed to increasing its dividend payout, with a 67% dividend rate for 2023, and aims to share its growth with investors [16].

Company Overview - Weike Technology specializes in the research, design, manufacturing, and sales of precision injection molds and has expanded into the production and sales of injection parts and health products, becoming a "mold integration" large-scale production enterprise [1] - The company has established overseas production bases in Germany and is expanding its global operations with facilities in Malaysia, Mexico, the USA, Singapore, and Vietnam since 2019 [1] - Weike has over 500 patents, including 27 authorized invention patents, and has been recognized as a key backbone enterprise in precision injection molds in China [2] Financial Performance - The company's gross profit margin is higher than that of its peers due to its technological leadership, customized small-batch production, and a client base that includes many Fortune 500 companies [3] - The gross profit margin is expected to experience a slow decline due to product structure adjustments and increased domestic market share, despite maintaining a relatively high level [4] - The target for net profit growth in 2025 is set at 20% year-on-year, aligning with the employee equity incentive plan [8] Market and Sales - As of the first three quarters of 2024, the company's export sales accounted for approximately 42%, but the actual figure is expected to exceed 60% due to certain sales being misclassified as domestic [8] - Export sales are primarily directed towards North America (29%), Europe (30%), and Asia (39%) [8] Product and Competitive Advantage - The core competitiveness of the fast-growing fashion small home appliance sector lies in the company's integrated manufacturing platform, which includes product design, mold design, mold manufacturing, injection production, and assembly [5] - The company maintains a high level of customer stickiness, particularly in long lifecycle sectors like automotive and medical, where switching costs for clients are significant [6]

关于厦门唯科模塑科技股份有限公司 部分首次公开发行前已发行限售股份上市流通的核查意见 国金证券股份有限公司（以下简称"保荐机构"）为厦门唯科模塑科技股份 有限公司（以下简称"唯科科技"或"公司"）首次公开发行股票并在创业板上 市的保荐机构，根据《证券发行上市保荐业务管理办法》、《深圳证券交易所创业 板股票上市规则》、《深圳证券交易所上市公司自律监管指引第 2 号——创业板上 市公司规范运作》等有关规定，对唯科科技部分首次公开发行前已发行限售股份 上市流通事项进行了核查，核查情况如下： 一、首次公开发行前已发行股份概况 中国证监会 2021 年 12 月 1 日核发了《关于同意厦门唯科模塑科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2021]3798 号），同意公司首次公 开发行股票的注册申请。公司首次公开发行人民币普通股（A 股）股票 3,120 万 股，并于 2022 年 1 月 11 日在深圳证券交易所创业板上市。 公司首次公开发行前总股本为 93,600,000 股，首次公开发行后总股本为 124,800,000 股，其中：无流通限制及锁定安排的股票数量为 29,588,676 股，占 发 ...

证券代码：301196 证券简称：唯科科技 公告编号：2025-002 厦门唯科模塑科技股份有限公司 关于部分首次公开发行前已发行股份上市流通的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 特别提示： 1、本次解除限售的股份为厦门唯科模塑科技股份有限公司（以下简称"公 司"或"发行人"）部分首次公开发行前已发行股份； 2、本次解除限售股东户数共计 6 户，解除限售股份的数量为 29,950,000 股，占公司总股本的 24.00%，限售期为自公司首次公开发行并上市之日起 36 个 月； 3、本次解除限售的股份上市流通日期为 2025 年 1 月 13 日（星期一，因 2025 年 1 月 11 日为非交易日，故顺延至下一交易日）。 一、首次公开发行前已发行股份概况 中国证监会 2021 年 12 月 1 日核发了《关于同意厦门唯科模塑科技股份有限 公司首次公开发行股票注册的批复》（证监许可[2021]3798 号），同意公司首 次公开发行股票的注册申请。公司首次公开发行人民币普通股（A 股）股票 3,120 万股，并于 2022 年 1 月 11 ...

证券代码：301196 证券简称：唯科科技 公告编号：2025-001 厦门唯科模塑科技股份有限公司 关于回购股份的进展公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 厦门唯科模塑科技股份有限公司（以下简称"公司"）于 2024 年 1 月 27 日 召开第二届董事会第九次会议、第二届监事会第八次会议，审议通过《关于回购 股份方案的议案》，同意公司使用自有资金不低于人民币 5,000 万元（含）且不 超过人民币 1 亿元（含）以集中竞价交易方式回购公司股份用于实施股权激励或 员工持股计划，回购价格不超过人民币 45 元/股（含），回购期限自公司董事会 审议通过本次回购股份方案之日起 12 个月内。具体内容详见公司在巨潮资讯网 （http://www.cninfo.com.cn）披露的相关公告。 根据《上市公司股份回购规则》《深圳证券交易所上市公司自律监管指引第 9 号——回购股份》等相关规定，公司应当在每个月的前三个交易日内披露截至 上月末的回购进展情况。现将公司截至 2024 年 12 月 31 日回购股份的进展情况 公告如下： 一、回购股份的进展情况 ...

| 相应的审批程序和披露义务 | （五）募集资金使用 | | | | | | --- | --- | --- | --- | --- | --- | | 现场检查手段：查阅公司募集资金管理制度及其制定、审批的相关三会文件；查阅募集 | 资金台账，核查募集资金使用情况；查阅募集资金存放三方协议及相关的会议审批文 | | | | | | 件，查阅公司各募集资金专项账户的银行对账单，抽查募集资金相关合同、资金使用审 | 批单、支付凭证等材料；对相关人员进行访谈等，了解募集资金使用情况。 | | | | | | 1.是否在募集资金到位后一个月内签订三方监管协议 | √ | 2.募集资金三方监管协议是否有效执行 | √ | | | | 3.募集资金是否不存在第三方占用、违规进行委托理财 | √ | 等情形 | | | | | 4.是否不存在未履行审议程序擅自变更募集资金用途、 | 暂时补充流动资金、置换预先投入、改变实施地点等情 | √ | | | | | 形 | 5.使用闲置募集资金暂时补充流动资金、将募集资金投 | | | | | | 向变更为永久性补充流动资金或者使用超募资金补充流 | √ | 动资金或者偿还银行 ...

国金证券股份有限公司 关于厦门唯科模塑科技股份有限公司 2024年度持续督导培训情况的报告 国金证券股份有限公司（以下简称"国金证券"）作为厦门唯科模塑科技股份有 限公司（以下简称"唯科科技"或"公司"）首次公开发行股票并在创业板上市及持续 督导的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证券交易所创 业板股票上市规则》《深圳证券交易所上市公司自律监管指引第13号——保荐业务》 等有关法律法规的规定，对唯科科技董事、监事、高级管理人员及部分中层干部， 上市公司控股股东、实际控制人等相关人员进行了2024年度持续督导培训。现将培 训情况报告如下： 一、培训基本情况 培训时间：2024年12月13日 培训地点：唯科科技会议室 培训方式：现场和线上授课相结合 培训对象：唯科科技董事、监事及高级管理人员、中层及以上管理人员、 控股股东、实际控制人等相关人员 二、培训主要内容 1、资本市场近期重要政策分享； 2、与上市公司规范运作相关法规讲解； 3、上市公司募集资金使用违规案例分享。 三、培训效果 本次持续督导培训工作，唯科科技培训人员认真学习，并给予了积极配合， 保证了本次培训的顺利开展。通过本次培训，唯科 ...

重要提示： 1、本次股东大会未出现否决议案的情况。 证券代码：301196 证券简称：唯科科技 公告编号：2024-078 厦门唯科模塑科技股份有限公司 2024 年第一次临时股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或重大遗漏。 2、本次股东大会未涉及变更以往股东大会已通过的决议。 3、根据法律、法规、规章和规范性文件对上市公司回购股份事宜的相关规定，上市 公司回购专用账户中的股份不享有股东大会表决权，截止本次股东大会股权登记日，公 司总股本 124,800,000 股，公司回购专用证券账户持有股份 428,371 股，故公司本次股 东大会有表决权股份总数为 124,371,629 股。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开的时间： （1）现场会议时间：2024 年 12 月 4 日（星期三）下午 2:00 （2）网络投票时间：2024 年 12 月 4 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 12 月 4 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00；通过深 ...

国浩律师（上海）事务所 股东大会法律意见书 国浩律师（上海）事务所 关于厦门唯科模塑科技股份有限公司 2024 年第一次临时股东大会的法律意见书 致：厦门唯科模塑科技股份有限公司 厦门唯科模塑科技股份有限公司（以下简称"公司"）2024 年第一次临时股东 大会（以下或称"本次股东大会"）于 2024 年 12 月 4 日召开，国浩律师（上海） 事务所（以下简称"本所"）接受公司的委托，指派律师（以下简称"本所律师"） 出席会议，并依据《中华人民共和国证券法》《中华人民共和国公司法》、中国证 券监督管理委员会《上市公司股东大会规则》和《厦门唯科模塑科技股份有限公司 章程》（以下简称"《公司章程》"）出具本法律意见书。 本所律师已经按照有关法律、行政法规及规范性文件的规定对公司本次股东大 会召集、召开程序是否合法以及是否符合《公司章程》规定、出席会议人员的资格、 召集人资格的合法有效性和股东大会表决程序、表决结果的合法有效性发表法律意 见。法律意见书中不存在虚假、严重误导性陈述及重大遗漏，否则愿意承担相应的 法律责任。 本所律师是根据对事实的了解和对法律的理解发表法律意见。 本法律意见书依据国家有关法律、行政法规 ...